December 19, 2017 / 12:32 PM / in 10 months

Shire says Hunter syndrome treatment fails in key study

Dec 19 (Reuters) - Shire Plc’s investigational drug for treating pediatric patients with Hunter syndrome and cognitive impairment failed to meet the main goal of a late-stage trial.

The clinical trial evaluating SHP609, previously known as HGT-2310, did not meet either its primary or its key secondary endpoints, London-listed pharmaceutical firm said in a statement on Tuesday. (Reporting By Justin George Varghese in Bengaluru; Editing by Bernard Orr)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below